Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
ProShares Pet Care ETF (PAWZ) Eyes +12% Move Toward $62 Objective

ProShares Pet Care ETF (PAWZ) Eyes +12% Move Toward $62 Objective

Key Takeaways

  • The $62 target used here is a fallback objective drawn from public discussion, not a direct analyst consensus, since ETFs are rarely assigned sell-side price targets.
  • ProShares Pet Care ETF (PAWZ) trades near $55, so reaching $62 implies a roughly 12% gain—a substantial move for a thematic fund.
  • The objective reflects weighted implied analyst targets of PAWZ's underlying holdings (a range of roughly $50 to $68 has been published) and technical projections into the low-to-mid $60s.
  • Support comes from resilient pet-care spending and exposure to market leaders such as IDEXX Laboratories (IDXX), Chewy (CHWY), and Zoetis (ZTS).
  • Key risks include the fund's small AUM (assets under management) of about $35 million, a 0.50% expense ratio, concentration in healthcare and consumer names, and the $57.44 52-week high acting as resistance.
  • For more information, explore PAWZ's Major News, Today's Price Move, Forecast, and Earnings pages.

How the $62 Target Came Into View

PAWZ is an exchange-traded fund, not an individual stock, so it does not carry the kind of direct analyst price targets applied to companies. Instead, the $62 objective is a fallback figure grounded in public discussion: weighted implied analyst price targets calculated from the ETF's underlying holdings and technical projections. Independent services that aggregate analyst targets across PAWZ's component stocks have published implied 12-month objectives around $58 on average, with a reported range from roughly $50 to $68. Because $58 sits only a few percent above the current price, this article uses a more meaningful $62 objective, which aligns with the upper portion of that implied range and with technical analysis pointing toward the low-to-mid $60s. This is a publicly discussed price objective, not a formal consensus, and it should not be read as a prediction. I also checked this using Tickeron’s AI Pattern Search Engine to see how the fund compares to peers in the sector.

Current Market Position and Path Toward the Target

PAWZ trades near $55, versus a 52-week range of roughly $45.96 to $57.44. Reaching $62 would require a gain of about 12%, a substantial move that would push the fund decisively to new highs. The ProShares Pet Care ETF tracks the FactSet Pet Care Index, a tier-weighted basket of global companies tied to pet ownership, launched in November 2018 with a 0.50% expense ratio. Sector exposure skews heavily toward healthcare (around 43%), followed by consumer cyclical and consumer defensive names. The largest positions include IDEXX Laboratories, Chewy, Zoetis, and Freshpet (FRPT), with Trupanion (TRUP) and several European names such as Virbac and Nestlé rounding out the top ten. Because the fund's performance is driven by its largest holdings, any path to $62 likely depends on continued strength in veterinary diagnostics, pet pharmaceuticals, and online pet retail.

What Could Support a Move Toward the Target

The pet-care theme benefits from relatively inelastic, recurring consumer spending, which has historically held up through economic slowdowns. Zoetis and IDEXX, which together represent a large share of the portfolio, are leaders in animal health with recurring revenue from diagnostics and pharmaceuticals. Chewy and Freshpet expose the fund to the growing shift toward premium pet food and e-commerce. Broadly, if the fund's healthcare-heavy positioning benefits from steady demand and its growth-oriented holdings sustain earnings momentum, a re-rating toward the low-$60s is plausible. A rotation back into consumer and healthcare growth, combined with easing interest-rate pressure, could also help sentiment. Notably, PAWZ's weighted forward P/E (price-to-earnings ratio) has been estimated near 16, below category peers, leaving room for multiple expansion if growth holds.

What Could Prevent the Target From Being Reached

Several structural risks weigh on the fund. Its AUM of roughly $35 million is small by ETF standards, sitting near levels where closure risk becomes a consideration for niche products, and its bid-ask spreads are wide relative to broad-market funds. A 0.50% fee is on the higher end for a passive thematic vehicle, and portfolio turnover has been elevated. Concentration is another concern: the top three holdings account for roughly 30% of assets, and the top ten approach 70%, meaning weakness in a few large names can dominate returns. If animal-health leaders face pricing pressure, competition, or slower clinic traffic, or if higher-for-longer interest rates continue to compress growth-stock valuations, the fund could struggle to clear its prior highs rather than break toward $62.

Technical Levels and Market Structure

The $57.44 52-week high is the most important near-term obstacle; it represents both a prior peak and a natural resistance level. A sustained move above that area would leave the round-number $60 level as the next psychological hurdle before $62 comes into view. On the downside, the mid-$50s and the area near the 52-week low around $46 provide reference support zones. The fund has traded in a broad range over the past year, and a decisive breakout above prior highs would likely be required for the target to become reachable.

Time Horizon and What Investors Should Monitor

Implied analyst targets on the underlying holdings generally reflect a roughly 12-month forward horizon, though no single timeline applies to the ETF itself. Investors should watch quarterly earnings and guidance from the largest holdings—especially Zoetis, IDEXX, Chewy, and Freshpet—along with any analyst target revisions on those names. Macroeconomic factors also matter: interest-rate decisions, consumer-spending data, and shifts in sector rotation between growth and defensive equities can all influence a thematic fund like PAWZ. Fund-level metrics such as AUM trends and trading volume are worth monitoring given the fund's small size. From what I see, keeping an eye on these elements helps clarify whether momentum is building.

Monitoring PAWZ With AI Tools

In my own process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to stay on top of shifts in thematic funds like this one. The platform uses artificial intelligence to scan thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on technical behavior and market conditions. For a smaller, niche product such as PAWZ, these automated alerts can highlight changes in momentum that might otherwise be easy to miss. I find the signals particularly helpful as a complement to manual review of holdings and macro data.

Final Assessment

Whether PAWZ can reach $62 depends on a confluence of factors rather than any single catalyst. The roughly 12% move would require the fund to clear its 52-week high and sustain momentum through its largest holdings. The pet-care theme offers resilient demand and exposure to durable animal-health franchises, which supports the objective, but the fund's small AUM, higher fee, concentration, and dependence on growth-stock sentiment are meaningful obstacles. Published implied analyst targets for the underlying holdings span a wide range, underscoring genuine disagreement about valuation. Investors should treat $62 as a discussion-based reference point, not a forecast, and monitor holdings-level earnings, rate policy, and fund flows before drawing conclusions. One thing that stands out is how much the outcome hinges on steady performance from the top holdings.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PAWZ

PAWZ saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for PAWZ moved out of overbought territory on November 16, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 65 similar instances where the indicator exited the overbought zone. In 57 of the 65 cases the stock moved lower. This puts the odds of a downward move at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for PAWZ moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 17 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.

The Moving Average Convergence Divergence Histogram (MACD) for PAWZ turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 35 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PAWZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

PAWZ broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

PAWZ moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PAWZ crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 61%.

Following a +5.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where PAWZ advanced for three days, in 227 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

The Aroon Indicator entered an Uptrend today. In 158 of 229 cases where PAWZ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.

Notable companies

The most notable companies in this group are Merck & Co (NYSE:MRK), Colgate-Palmolive Company (NYSE:CL), ZOETIS (NYSE:ZTS), General Mills (NYSE:GIS), Tractor Supply Co (NASDAQ:TSCO), Elanco Animal Health (NYSE:ELAN), Chewy (NYSE:CHWY).

Industry description

The investment seeks investment results, before fees and expenses, that track the performance of the FactSet Pet Care Index (the "index"). The fund invests in financial instruments that ProShare Advisors believes, in combination, should track the performance of the index. The index is designed to measure the performance of companies that stand to benefit from interest in or resources spent on pet ownership. Under normal circumstances, it will invest at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.

Market Cap

The average market capitalization across the ProShares Pet Care ETF (PAWZ) ETF is 41.62B. The market cap for tickers in the group ranges from 847.8M to 362.01B. MRK holds the highest valuation in this group at 362.01B. The lowest valued company is WOOF at 847.8M.

High and low price notable news

The average weekly price growth across all stocks in the ProShares Pet Care ETF (PAWZ) ETF was 7%. For the same ETF, the average monthly price growth was 34%, and the average quarterly price growth was 16%. TRUP experienced the highest price growth at 7%, while CHWY experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the ProShares Pet Care ETF (PAWZ) ETF was 9%. For the same stocks of the ETF, the average monthly volume growth was -15% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 70
P/E Growth Rating: 56
Price Growth Rating: 41
SMR Rating: 58
Profit Risk Rating: 78
Seasonality Score: 25 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.